When your investment case breaks down, why not just do the decent thing?
ApexOnco Front Page
Recent articles
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
AVZO-023 follows AVZO-021 into clinical trials.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
